Thanks Idit. I guess you are priming me for Round-2.
I don't think double pricing is fair. Or withholding options that would benefit patients. Yet GILD appears to be right concerning extended 24-week dosing. I wasn't aware we would see this data before the the PDUFA date (obviously I wasn't paying close enough attention). My personal feeling is a 1500 basis point efficacy margin between interferon-based and oral therapy is a fair trade-off. If Sofo/PegRiba readout at a 100% SVR rate (which isn't going to happen) GILD still caught the bottom end of this scale.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.